X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (93) 93
female (61) 61
male (58) 58
aged (57) 57
middle aged (50) 50
cardiac & cardiovascular systems (39) 39
abridged index medicus (37) 37
double-blind method (37) 37
myocardial infarction (32) 32
risk (27) 27
risk factors (27) 27
medicine, general & internal (25) 25
stroke (25) 25
mortality (24) 24
drug therapy (23) 23
heart failure (23) 23
treatment outcome (23) 23
aspirin (22) 22
heart attacks (21) 21
anticoagulants (19) 19
drug therapy, combination (18) 18
cardiovascular disease (17) 17
clopidogrel (17) 17
acute coronary syndromes (16) 16
cardiovascular diseases (16) 16
hemorrhage - chemically induced (16) 16
prevention (16) 16
bleeding (15) 15
care and treatment (15) 15
cerebral infarction (15) 15
clinical trials (15) 15
health risk assessment (14) 14
medical and health sciences (13) 13
medicin och hälsovetenskap (13) 13
metaanalysis (13) 13
myocardial-infarction (13) 13
acute coronary syndrome (12) 12
analysis (12) 12
cardiovascular diseases - mortality (12) 12
diabetes (12) 12
drug administration schedule (12) 12
electrocardiography (12) 12
follow-up studies (12) 12
heart diseases (12) 12
ischemia (12) 12
myocardial infarction - drug therapy (12) 12
percutaneous coronary intervention (12) 12
physics (12) 12
research (12) 12
studies (12) 12
therapy (12) 12
anticoagulants - therapeutic use (11) 11
cardiovascular diseases - prevention & control (11) 11
genetics & heredity (11) 11
hospitalization (11) 11
patients (11) 11
schizophrenia (11) 11
stroke - prevention & control (11) 11
cardiology (10) 10
coronary artery disease (10) 10
disease (10) 10
dosage and administration (10) 10
guidelines (10) 10
kaplan-meier estimate (10) 10
myocardial infarction - diagnosis (10) 10
patient outcomes (10) 10
risk assessment (10) 10
schizophrenia - genetics (10) 10
secondary prevention (10) 10
stroke - epidemiology (10) 10
thrombosis (10) 10
usage (10) 10
acute myocardial-infarction (9) 9
aspirin - adverse effects (9) 9
clinical medicine (9) 9
klinisk medicin (9) 9
medical research (9) 9
myocardial infarction - mortality (9) 9
no (9) 9
prognosis (9) 9
warfarin (9) 9
adult (8) 8
aged, 80 and over (8) 8
algorithms (8) 8
anticoagulants - adverse effects (8) 8
atrial fibrillation (8) 8
atrial fibrillation - drug therapy (8) 8
cardiovascular (8) 8
coronary vessels (8) 8
death (8) 8
diabetes mellitus (8) 8
dose-response relationship, drug (8) 8
genetics (8) 8
genomics (8) 8
heart attack (8) 8
hemorrhage (8) 8
myocardial infarction - epidemiology (8) 8
outcomes (8) 8
platelet aggregation inhibitors - adverse effects (8) 8
platelet aggregation inhibitors - therapeutic use (8) 8
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England journal of medicine, ISSN 1533-4406, 2019, Volume 380, Issue 16, pp. 1509 - 1524
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2011, Volume 365, Issue 11, pp. 981 - 992
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2011, Volume 365, Issue 8, pp. 699 - 708
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2015, Volume 385, Issue 9982, pp. 2067 - 2076
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2012, Volume 367, Issue 14, pp. 1297 - 1309
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2016, Volume 375, Issue 6, pp. 534 - 544
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2013, Volume 369, Issue 14, pp. 1327 - 1335
Alogliptin, a new antihyperglycemic agent of the DPP-4 class, was shown to have no significant effect on cardiovascular risk over a median treatment period of... 
INHIBITOR ALOGLIPTIN | MEDICINE, GENERAL & INTERNAL | CARDIOVASCULAR SAFETY | MELLITUS | OUTCOMES | MYOCARDIAL-INFARCTION | Hypoglycemic Agents - therapeutic use | Double-Blind Method | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Uracil - therapeutic use | Male | Myocardial Infarction - complications | Myocardial Infarction - drug therapy | Uracil - adverse effects | Angina, Unstable - drug therapy | Piperidines - therapeutic use | Angina, Unstable - complications | Piperidines - adverse effects | Cardiovascular Diseases - mortality | Female | Aged | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Diabetes Mellitus, Type 2 - complications | Uracil - analogs & derivatives | Type 2 diabetes | Care and treatment | Acute coronary syndrome | Patient outcomes | Risk factors | Myocardial infarction | Heart attacks | Cardiovascular disease | Angina | Drug development | Hemoglobin | Diabetes mellitus (non-insulin dependent) | Drug dosages | Cerebral infarction | Stroke | Peptidase | Statistical analysis | Diabetes mellitus | Pancreatitis | Committees | FDA approval | Hypoglycemia | Angina pectoris | Studies | Product development | Diabetes | Acute coronary syndromes | Cardiovascular diseases | Health risk assessment | Cancer
Journal Article